Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026

Loading news article.

Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026 | WAPE

Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026

Article summary

Related companies

Comments —